Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Children Aged 5–11 Years — United States, November 2021
Kate R. Woodworth, Danielle Moulia, Jennifer P. Collins, et al.
MMWR Morbidity and Mortality Weekly Report (2021) Vol. 70, Iss. 45, pp. 1579-1583
Open Access | Times Cited: 153

Showing 1-25 of 153 citing articles:

COVID-19 Vaccine Safety in Children Aged 5–11 Years — United States, November 3–December 19, 2021
Anne M. Hause, James Baggs, Paige Marquez, et al.
MMWR Morbidity and Mortality Weekly Report (2021) Vol. 70, Iss. 5152, pp. 1755-1760
Open Access | Times Cited: 163
Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5–11 Years and Adolescents Aged 12–15 Years — PROTECT Cohort, July 2021–February 2022
Ashley Fowlkes, Sarang K. Yoon, Karen Lutrick, et al.
MMWR Morbidity and Mortality Weekly Report (2022) Vol. 71, Iss. 11, pp. 422-428
Open Access | Times Cited: 162
Association of Prior BNT162b2 COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection in Children and Adolescents During Omicron Predominance
Katherine E. Fleming-Dutra, Amadea Britton, Nong Shang, et al.
JAMA (2022) Vol. 327, Iss. 22, pp. 2210-2210
Open Access | Times Cited: 139
BNT162b2 Vaccine Effectiveness against Omicron in Children 5 to 11 Years of Age
Chandra J. Cohen-Stavi, Ori Magen, Noam Barda, et al.
New England Journal of Medicine (2022) Vol. 387, Iss. 3, pp. 227-236
Open Access | Times Cited: 87
Characteristics and Clinical Outcomes of Children and Adolescents Aged <18 Years Hospitalized with COVID-19 — Six Hospitals, United States, July–August 2021
Valentine Wanga, Megan E. Gerdes, Dallas S. Shi, et al.
MMWR Morbidity and Mortality Weekly Report (2021) Vol. 70, Iss. 5152, pp. 1766-1772
Open Access | Times Cited: 96
Multisystem Inflammatory Syndrome in Children—United States, February 2020–July 2021
Allison D. Miller, Laura D. Zambrano, Anna R Yousaf, et al.
Clinical Infectious Diseases (2021) Vol. 75, Iss. 1, pp. e1165-e1175
Open Access | Times Cited: 92
Interim Recommendations of the Advisory Committee on Immunization Practices for Use of Moderna and Pfizer-BioNTech COVID-19 Vaccines in Children Aged 6 Months–5 Years — United States, June 2022
Katherine E. Fleming-Dutra, Megan Wallace, Danielle Moulia, et al.
MMWR Morbidity and Mortality Weekly Report (2022) Vol. 71, Iss. 26, pp. 859-868
Open Access | Times Cited: 65
SARS-CoV-2 infection in pediatric population before and during the Delta (B.1.617.2) and Omicron (B.1.1.529) variants era
Haifa Khemiri, Kaouther Ayouni, Henda Triki, et al.
Virology Journal (2022) Vol. 19, Iss. 1
Open Access | Times Cited: 64
Safety of COVID-19 Vaccination in United States Children Ages 5 to 11 Years
Anne M. Hause, David K. Shay, Nicola P. Klein, et al.
PEDIATRICS (2022) Vol. 150, Iss. 2
Open Access | Times Cited: 48
Multisystem Inflammatory Syndrome in Children During Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Delta and Omicron Variant Circulation—United States, July 2021–January 2022
Allison D. Miller, Anna R Yousaf, Ethan Bornstein, et al.
Clinical Infectious Diseases (2022) Vol. 75, Iss. Supplement_2, pp. S303-S307
Open Access | Times Cited: 46
Development of therapeutic vaccines for the treatment of diseases
Yaomei Tian, Die Hu, Yuhua Li, et al.
Molecular Biomedicine (2022) Vol. 3, Iss. 1
Open Access | Times Cited: 44
Safety and immunogenicity of BNT162b2 mRNA COVID-19 vaccine in adolescents with rheumatic diseases treated with immunomodulatory medications
Merav Heshin‐Bekenstein, Amit Ziv, Nataša Toplak, et al.
Lara D. Veeken (2022) Vol. 61, Iss. 11, pp. 4263-4272
Open Access | Times Cited: 43
BNT162b2 mRNA Vaccination Against Coronavirus Disease 2019 is Associated With a Decreased Likelihood of Multisystem Inflammatory Syndrome in Children Aged 5–18 Years—United States, July 2021 – April 2022
Laura D. Zambrano, Margaret M. Newhams, Samantha M. Olson, et al.
Clinical Infectious Diseases (2022) Vol. 76, Iss. 3, pp. e90-e100
Open Access | Times Cited: 38
Comparison of Influenza and Coronavirus Disease 2019–Associated Hospitalizations Among Children Younger Than 18 Years Old in the United States: FluSurv-NET (October–April 2017–2021) and COVID-NET (October 2020–September 2021)
Miranda J. Delahoy, Dawud Ujamaa, Christopher A. Taylor, et al.
Clinical Infectious Diseases (2022) Vol. 76, Iss. 3, pp. e450-e459
Open Access | Times Cited: 37
Reactogenicity of Simultaneous COVID-19 mRNA Booster and Influenza Vaccination in the US
Anne M. Hause, Bicheng Zhang, Xin Yue, et al.
JAMA Network Open (2022) Vol. 5, Iss. 7, pp. e2222241-e2222241
Open Access | Times Cited: 37
Safety of Ancestral Monovalent BNT162b2, mRNA-1273, and NVX-CoV2373 COVID-19 Vaccines in US Children Aged 6 Months to 17 Years
Mao Hu, Azadeh Shoaibi, Yuhui Feng, et al.
JAMA Network Open (2024) Vol. 7, Iss. 4, pp. e248192-e248192
Open Access | Times Cited: 7
COVID-19 Vaccine Acceptance Among US Parents: A Nationally Representative Survey
E. Adrianne Hammershaimb, Lyndsey Cole, Yuanyuan Liang, et al.
Journal of the Pediatric Infectious Diseases Society (2022) Vol. 11, Iss. 8, pp. 361-370
Open Access | Times Cited: 34
Recent advances in nanotechnology-based COVID-19 vaccines and therapeutic antibodies
Lanying Du, Yang Yang, Xiujuan Zhang, et al.
Nanoscale (2022) Vol. 14, Iss. 4, pp. 1054-1074
Open Access | Times Cited: 31
Estimated BNT162b2 Vaccine Effectiveness Against Infection With Delta and Omicron Variants Among US Children 5 to 11 Years of Age
Farid Khan, Jennifer L. Nguyen, Tanya Singh, et al.
JAMA Network Open (2022) Vol. 5, Iss. 12, pp. e2246915-e2246915
Open Access | Times Cited: 31
Safety of the BNT162b2 COVID-19 Vaccine in Children Aged 5 to 17 Years
Mao Hu, Hui Lee Wong, Yuhui Feng, et al.
JAMA Pediatrics (2023) Vol. 177, Iss. 7, pp. 710-710
Open Access | Times Cited: 20
Quantitative Benefit–Risk Assessment of Vaccination Against COVID‐19: A Systematic Review
E. Claire Newbern, Lea Wildisen, Rita Verstraeten, et al.
Pharmacoepidemiology and Drug Safety (2025) Vol. 34, Iss. 2
Open Access
Attitude and Acceptance of COVID-19 Vaccine in Parents and Adolescents: A Nationwide Survey
Hyunju Lee, Young June Choe, Shinkyeong Kim, et al.
Journal of Adolescent Health (2022) Vol. 71, Iss. 2, pp. 164-171
Open Access | Times Cited: 25
COVID-19 vaccine and menstrual conditions in female: data analysis of the Vaccine Adverse Event Reporting System (VAERS)
Bing Zhang, Yu Xiao, Jinxing Liu, et al.
BMC Women s Health (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 25
A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection
Juan Shi, Jian Zheng, Wanbo Tai, et al.
Journal of Virology (2022) Vol. 96, Iss. 17
Open Access | Times Cited: 24
Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence and Reported Coronavirus Disease 2019 Cases in US Children, August 2020–May 2021
Alexia Couture, B. Casey Lyons, Megha Mehrotra, et al.
Open Forum Infectious Diseases (2022) Vol. 9, Iss. 3
Open Access | Times Cited: 23
Page 1 - Next Page

Scroll to top